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Nicorandil, a drug approved for the treatment of
ischaemic heart disease, is believed to have a dual
properties. The intrinsic mechanism of the drug
(selective activation of K+ATP channels at the sarco-
lemmal and mitrochondrial level) allows coronary
and peripheral vasodilatation with subsequent
reduction of preload and afterload. Secondly,
because of the role K+ATP channels in ischaemic
preconditioning, nicorandil has been attributed
cardioprotective effects.1
The drug has been available in Europe for years,
classified as a new class of therapy for coronary
artery disease, but failed till now to truly penetrate
on the ‘European market’. The large scaled, ran-
domized IONA trial evaluated the efficacy of nic-
orandil on top of ‘conventional’ antianginal drugs
for the treatment of stable angina pectoris.2 The
primary end-point (a composite of cardiac death,
myocardial infarction, unplanned hospital admis-
sion for chest pain) occurred significantly less in the
nicorandil (13.1%) then in the placebo group
(15.5%, P=0.014). Nevertheless, only about half of
patients were on -blockers and ‘unplanned hospi-
tal admission for chest pain’ is a very weak end-
point despite the randomized character of the trial.
Inherent of these limitations, nicorandil may be
considered as a safe additional drug to -blockers
for angina relief in patients with stable angina
pectoris. Weather, it may be an alternative to
-blockers in post myocardial infarction patients
remains to be established.
Nicorandil has a long tradition in Japan, where it
has been studied extensively. The present issue of
the journal publishes two papers from Japan. The
first study by Matsuo et al. evaluates again the
efficacy of nicorandil in ischaemic preconditioning
in the human angioplasty model while the second
paper by Izawa et al. investigates the impact of the
drug on left ventricular filling pressures in exercis-
ing patients with hypertrophic cardiomyopathy.3,4
A potential benefit of the drug is demonstrated in
both trials, characterized by a heavy, ‘high-tech’
methodology applied to small study cohort.
Nevertheless, they merit our consideration as
both authors have improved and extended prior
research in the field, providing thereby relatively
solid data.
Matsuo et al. previously demonstrated by simple
ST-segment analysis that nicorandil enhances pre-
conditioning in the human PTCA model.5 However,
the potential contribution of collateral blood flow
was not adequately assessed. In the present study,
a homogeneous group of 44 patients with isolated
proximal LAD stenosis and normal left ventricular
function, was randomized to intravenous nicorandil
or saline prior to angioplasty.3 In addition to ST-
segment analysis, 99mTc tetrofosmin SPECT acqui-
sition was performed at the end of the PCTA as a
surrogate for myocardial perfusion to the related
myocardium. A trend but no significant flow
increase to the ischemic bed was demonstrated
together with a significant attenuation of ST-
segment elevation in the nicorandil group. This
implies that nicorandil seems to possess a
cardioprotective effect independent of myocardial
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(collateral) blood flow to the ischaemic bed. The
message is clear and easily understood.
The second paper by Izawa et al. studied the
effect of nicorandil on left ventricular end-diastolic
pressure during exercise in patients with non-
obstructive hypertrophic cardiomyopathy.4 These
authors too, added an additional step to previous
research. They could previously distinguish a dis-
tinct behaviour of left ventricular filling pressures
during exercise in these patients depending of the
severity of myocardial hypertrophy.6 A continuous
increase in pressure was observed in patients with
severe hypertrophy, while those with mild hyper-
trophy experienced a biphasic pattern with an
initial increase following by a decrease prior to
peak exercise. Both groups could further be distin-
guished by more severe Thallium-201 scintigraphy
perfusion defects in case of severe hypertrophy.
The biphasic pattern in the mild hypertrophy group
was abolished by pre-treatment with propanolol,
suggesting a -adrenergic mediated coronary
vasodilatation induced by exercise. Vasodilatation
may prevent myocardial ischaemia in a vascular
bed that has not grown in proportion to the hyper-
trophy, therefore preventing further rise in filling
pressures. Without providing clear anatomic cut-off
values to predict these haemodynamic alterations,
the authors have now conducted a second trial
published in this issue of the journal. A total of 23
patients with non-obstructive hypertrophic cardio-
myopathy were randomised to pre-treatment to
nicorandil or propanolol prior to any knowledge of
the haemodynamic conditions induced by exercise.
Again, patients could be categorized according to
the evolution of the pressure pattern during exer-
cise: gradual increase (13 patients, group 1) or a
biphasic pattern (10 patients, group 2). The current
study further confirmed their initial observation
that the pressure pattern was related to the extent
of myocardial hypertrophy and perfusion defects on
myocardial scintigraphy. After completion of the
first exercise, the study medication was adminis-
tered and exercise was repeated to analyse its
impact on left ventricular filling pressures. There-
fore, four subgroups were available for analysis:
group 1 (nicorandil: eight patients, propanolol: five
patients) and group 2 (nicorandil: four patients,
propanolol: six patients). Obviously, propanolol
produced the same effect as during their first
study with a disappearance of the biphasic
pattern in group 2. This biphasic pattern was main-
tained in group 2 after administration of nicorandil
but more importantly four out of eight patients in
group 1 converted from a gradual increase to a
biphasic pattern. The authors postulated that this
beneficial effect was related to an augmented
left ventricular contractility as a result of
improved ischaemia and its impact on the coronary
microcirculation.
The results of this complex investigation are
intriguing and many questions remain unanswered.
How may we predict the haemodynamic pattern in
these patients during exercise by non invasive
means? One may assume that even if all patients in
both studies are pooled, statistics may fail to pro-
duce clear anatomic or scintigraphic cut-off values
to predict the ‘bad’ patients. At a second level, not
all patients, who experience a gradual increase in
left ventricular filling pressures during exercise,
benefit from nicorandil administration. Even if a
potential mechanism (improvement in contractility
and decrease in ischaemia) is postulated, no single
clue to this beneficial effect in particular patients
is suggested. Significant epicardial coronary dis-
ease was not present but the authors do not provide
any insight into a potential abnormal resistance at
this level to potentially explain the failure of nic-
orandil in four patients in group 1.7 Intracoronary
pressure measurements may therefore have eluci-
dated one of the confounding factors interacting in
these patients.
What will be the clinical relevance of the studies
with nicorandil in the present issue of the journal?
Both papers indicate that nicorandil may act ben-
eficial at the myocardial cellular level. The first
investigation demonstrates a cardioprotective
effect during angioplasty independent of collateral
flow to the ischaemic bed. Tremendous progress
has been achieved in interventional cardiology in
recent years and interventions appear ‘easier and
quicker done with excellent angiographic results
and few clinical complications’. There are however
no ‘hard’ clinical data to state this common belief.
As operators expand their indications to more com-
plex clinical and angiographic conditions, one may
suggest a potential role for this drug in patients
with an anticipated high interventional risk. Fur-
thermore, the drug should probably more exten-
sively be investigated during reperfusion strategies
for acute myocardial infarction. Finally, in the par-
ticular setting of minimal invasive cardiac surgery
further research seems indicated. The second
paper again is only a ‘second’ small step. Complex
investigation with invasive haemodynamic assess-
ment during exercise in patients with non obstruc-
tive cardiomyopathy might allow selection of
patients who benefit ‘acutely and in the exper-
imental setting’ from the drug. At present, we
ignore the clinical impact of this therapy and lack
non invasive tools to guide us. However, as in many
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success stories, we are confident that a ‘third’
episode will further reveal current uncertainties.
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